Science Explorer Back to mapMap

Angiogenesis and VEGF in Cancer

Angiogenesis and VEGF in Cancer is a research topic within Molecular Biology. Science Explorer counts 38k research works in it since 1950. 9.9% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the molecular mechanisms of angiogenesis, including the role of VEGF, endothelial progenitor cells, pericytes, and anti-angiogenic therapy in regulating tumor vasculature and vascular function. It explores the signaling pathways, therapeutic targets, and clinical applications related to angiogenesis.

  • VEGF
  • endothelial progenitor cells
  • tumor angiogenesis
  • anti-angiogenic therapy
  • vascular endothelial growth factor
  • pericytes
  • vascular normalization
  • endothelial cell behavior
  • tumor vasculature
  • angiogenic signaling
Research works
38k
fractional, since 1950
In the world top 10%
3.8k
per year above
Top-10% rate
9.9%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
-14%
the tick is no change
Largest producer
China
39% of the 10 largest, 2022-now

Which countries lead Angiogenesis and VEGF in Cancer research?

By volume, China and the United States publish the most (1.3k and 922 works in 2022-now).

By volume, 2022-now

  1. 1 China 1.3k works
  2. 2 United States 922 works
  3. 3 Japan 228 works
  4. 4 Germany 184 works
  5. 5 Italy 156 works
  6. 6 India 151 works
  7. 7 United Kingdom 139 works
  8. 8 South Korea 127 works
  9. 9 France 96 works
  10. 10 Russia 87 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

China: 38.8%United States: 27.0%Japan: 6.7%Germany: 5.4%6 others listed: 22.1%39%largest
China1,325 · 38.8%United States922 · 27.0%Japan228 · 6.7%Germany184 · 5.4%6 others listed755 · 22.1%

Shares of the rows listed above, not of the whole node.

Which institutions lead Angiogenesis and VEGF in Cancer research?

By volume in 2022-now, Harvard University publishes the most Angiogenesis and VEGF in Cancer research, followed by Sun Yat-sen University and Shanghai Jiao Tong University.

Who are the leading researchers in Angiogenesis and VEGF in Cancer?

The most-cited researchers publishing on Angiogenesis and VEGF in Cancer include Robert John Tibshirani, Bert Vogelstein and Jost Bruno Jonas.

  1. 1 Robert John Tibshirani United States 396k citations
  2. 2 Bert Vogelstein United States 373k citations
  3. 3 Jost Bruno Jonas Germany 350k citations
  4. 4 Emelia J. Benjamin United States 341k citations
  5. 5 Jun Wang China 340k citations
  6. 6 Stephan Windecker Switzerland 338k citations
  7. 7 Giuseppe Remuzzi Italy 328k citations
  8. 8 Graeme J. Hankey Australia 316k citations
  9. 9 Gordon Henry Guyatt Canada 315k citations
  10. 10 Gregory Y.H. Lip United Kingdom 311k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Angiogenesis and VEGF in Cancer?

The most cited paper in Angiogenesis and VEGF in Cancer is "Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer" (Herbert I. Hurwitz, Louis Fehrenbacher, William F. Novotny et al., 2004), with 11,036 citations. Next come "Tumor Angiogenesis: Therapeutic Implications" (10,238) and "The biology of VEGF and its receptors" (9,633).

Most cited papers
#PaperReleasedCitations
1 Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer Herbert I. Hurwitz, Louis Fehrenbacher, William F. Novotny et al. · New England Journal of Medicine Open access 2 Jun 2004 11,036
2 Tumor Angiogenesis: Therapeutic Implications Louis M. Sherwood, Edith E. Parris, Judah Folkman · New England Journal of Medicine 18 Nov 1971 10,238
3 The biology of VEGF and its receptors Napoleone Ferrara, Hans‐Peter Gerber, Jennifer E. LeCouter · Nature Medicine 30 May 2003 9,633
4 Angiogenesis in cancer and other diseases Peter Carmeliet, Rakesh K. Jain · Nature Sep 2000 9,128
5 Isolation of Putative Progenitor Endothelial Cells for Angiogenesis Takayuki Asahara, Toyoaki Murohara, Alison B. Sullivan et al. · Science 14 Feb 1997 8,789
All 100 most cited papers, with filters and sorting

Where is Angiogenesis and VEGF in Cancer research done?

The largest centres of Angiogenesis and VEGF in Cancer research in 2022-now are Beijing (China), Shanghai (China), Guangzhou (China) and Seoul (South Korea). Among places with at least 20 works in it, it is an unusually large share of all research in Bari.

Largest cities, 2022-now

  1. 1 BeijingChina 136 works
  2. 2 ShanghaiChina 121 works
  3. 3 GuangzhouChina 95 works
  4. 4 SeoulSouth Korea 62 works
  5. 5 TokyoJapan 58 works
  6. 6 HangzhouChina 58 works
  7. 7 ChengduChina 50 works
  8. 8 NanjingChina 48 works
  9. 9 LondonUnited Kingdom 48 works
  10. 10 BostonUnited States 46 works

Where it is the local speciality

  1. BariIT · 24.7 works9.8×
← less than its size predicts1×more →

Location quotient: how much more of its research is in Angiogenesis and VEGF in Cancer than the world average.

See Angiogenesis and VEGF in Cancer on the map

Where is the best place to study Angiogenesis and VEGF in Cancer?

Among universities, judged by research, Harvard University, KU Leuven and Chinese Academy of Medical Sciences & Peking Union Medical College score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%20%40%mean 14.9%fractional works in this field (log) →share of work in the world top 10% →KU LeuvenZhejiang UniversityHarvard UniversityChinese Academy of M…
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Citation excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Harvard UniversityUnited States 65.413.1%3.8×47 -20.3%
2KU LeuvenBelgium 54.529.4%2.5×9 -33.5%
3Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 51.412.0%6.5×26 +29.3%
4Zhejiang UniversityChina 50.415.5%3.1×32 -4.9%
5University of Bari Aldo MoroItaly 49.95.6%17.6×22 +51.5%
6Sun Yat-sen UniversityChina 48.410.5%5.2×42 -29.4%
7Sichuan UniversityChina 48.419.4%3.1×27 -5.2%
8Shanghai Jiao Tong UniversityChina 47.912.7%3.7×41 -24.8%
9Heidelberg UniversityGermany 47.716.5%5.4×16 -15.5%
10Fudan UniversityChina 47.614.3%4.4×27 -8.4%

Universities only. The score blends citation excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Angiogenesis and VEGF in Cancer, country by country

Is Angiogenesis and VEGF in Cancer research growing?

Output in 2022-2025 was 14% lower than in 2018-2021, peaking in 2012.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Angiogenesis and VEGF in Cancer as a percentage of every work published that year, 0.016% in 2024.

still counting0.025%0.050%0.075%Angiogenesis and VEGF in Cancer0.018% in 202519801990200020102020

Fractional works of Angiogenesis and VEGF in Cancer over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Angiogenesis and VEGF in Cancer9.9% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Angiogenesis and VEGF in Cancer. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.